News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases [Yahoo! Finance]

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.

8/14/2025

04:15 pm

pstv

14.6%

BEAT

5/30/2025

04:15 pm

pstv

28.2%

MISS

Form 8-K PLUS THERAPEUTICS, INC. For: Jan 13

Form 424B4 PLUS THERAPEUTICS, INC.

Form EFFECT PLUS THERAPEUTICS, INC.

Form S-1MEF PLUS THERAPEUTICS, INC.

Form S-1 PLUS THERAPEUTICS, INC.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}